Diabetes, disparities, and Covid-19: Three intertwined ‘epidemics’ raise risk
For people with diabetes, a thicket of biological and socioeconomic factors make them more likely to suffer severe illness and die of Covid-19.
Related Articles
Early tests of H5N1 prevalence in milk suggest U.S. bird flu outbreak in cows is widespread
The prevalence of H5N1 genetic material in purchased milk products suggests the bird flu outbreak is far more widespread in cows than official counts indicate.
Washington kicks into gear on H5N1
The USDA and FDA are ramping up their response to the H5N1 bird flu.
Bernie Sanders targets ‘outrageously high price’ of Ozempic
Senate health committee chair Bernie Sanders has launched an investigation into the “outrageously high price” of Novo Nordisk’s blockbuster drugs Ozempic and Wegovy.
Equity, technology, and costs top of mind for life science’s leaders
Physicians, researchers, CEOs, reporters, and more gathered in downtown Boston Wednesday night to celebrate STAT’s 2024 STATUS List, which features 50
STAT Virtual Event | Tomorrow’s Trailblazers in Science
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. ach year, STAT chooses a new class of Wunderkinds, showcasing…
Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future
Amid layoffs and a hit to earnings, Bristol’s new CEO shares his vision for the future.
The grim reality of relocating to get access to gender-affirming care
No one should be forced to choose between the community they call home and being able to access the care their children need.
Shortages of generic drugs can’t be blamed solely on group purchasing organizations
The dominance of group purchasing organizations (GPOs) is often cited as a cause of generic drug shortages. The problem is more complicated than that.
Generative AI is supposed to save doctors from burnout. New data show it needs more training
New research from academic hospitals reveals significant limitations of large language models (LLMs) in medical settings.
Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved.